Imaging outcomes for neuroprotection and repair in multiple sclerosis trials

Nature Reviews Neurology

Volumn 5, Issue 5, 2009, Pages 256-266

  Barkhof, Frederik ^a   Calabresi, Peter A ^b   Miller, David H ^c   Reingold, Stephen C ^d  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d Scientific and Clinical Review Associates LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; GADOLINIUM; IRON OXIDE; LUCIFERASE; N ACETYLASPARTIC ACID; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; NEUROPROTECTIVE AGENT;

BRAIN ATROPHY; BRAIN EDEMA; BRAIN RADIOGRAPHY; BRAIN SIZE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; ENCEPHALITIS; GLIOSIS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; IMAGE ANALYSIS; IMAGE ENHANCEMENT; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OPTIC NEURITIS; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PLASTICITY; PRIORITY JOURNAL; REMYELINIZATION; REPRODUCIBILITY; REVIEW; SPINAL CORD ATROPHY; STEM CELL TRANSPLANTATION; VISUAL ACUITY; BRAIN; CLINICAL TRIAL; DRUG EFFECT; IMAGE PROCESSING; NERVE CELL PLASTICITY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME;

BRAIN; CLINICAL TRIALS AS TOPIC; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; NEURONAL PLASTICITY; NEUROPROTECTIVE AGENTS; TREATMENT OUTCOME;

EID: 68349107070     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2009.41     Document Type: Review

References (83)

1. Compston, A. & Coles, A. Multiple sclerosis. Lancet 372, 1502-1517 (2008).
2. Lopez-Diego, R. S. & Weiner, H. L. Novel therapeutic strategies for multiple sclerosis - a multifaceted adversary. Nat. Rev. Drug Discov. 7, 909-925 (2008).
3. Miller, D. H. et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann. Neurol. 39, 6-16 (1996).
4. Edan, G. et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: A randomised multicentre study of active disease using MRI and clinical criteria. J. Neurol. Neurosurg. Psychiatry 62, 112-118 (1997).
5. Miller, D. H. et al. controlled trial of natalizumab for relapsing multiple sclerosis. N. Eng. J. Med. 348, 68-72 (2003).
6. Polman, C. et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 64, 987-991 (2005).
7. Kappos, L. et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 255, 1124-1140 (2006).
8. O'Connor, P. W. et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66, 894-900 (2006).
9. Comi, G. et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: A multicentre, randomized, double-blind, placebo-controlled phase IIb study. Lancet 371, 2085-2092 (2008).
10. Kappos, L. et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting
11. multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 372, 1463-1472 (2008).
12. Zivadinov, R. et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 71, 136-144 (2008).
13. Simon, J. H. Brain atrophy in multiple sclerosis: What we know and would like to know. Mult. Scler. 12, 679-687 (2006).
14. Anderson, V. M., Bartlett, J. W., Fox, N. C., Fisniku, L. & Miller, D. N. Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: Sample size estimates. J. Neurol. 254, 1588-1594 (2007).
15. Altmann, D. R. et al. Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology 72, 595-601 (2009).
16. Chen, J. T. et al. Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis. Neurology 66, 1935-1937 (2006).
17. Tiberio, M. et al. Gray and white matter volume changes in early RRMS: A 2-year longitudinal study. Neurology 64, 1001-1007 (2005).
18. Sastre-Garriga, J. et al. Metabolic changes in normal-appearing gray and white matter are linked with disability in early primary progressive multiple sclerosis. Arch. Neurol. 62, 569-573 (2005).
19. Fisher, E., Lee, J.-C., Nakamura, K. & Rudick, R. A. Gray matter atrophy in multiple sclerosis: A longitudinal study. Ann. Neurol. 64 255-265 (2008).
20. Nakamura, K. & Fisher, E. Segmentation of brain magnetic resonance images for measurement of gray matter atrophy in multiple sclerosis patients. Neuroimage 44, 769-776 (2009).
21. Barkhof, F. Assessing treatment effects on axonal loss - evidence from MRI monitored clinical trials. J. Neurol. 251 (Suppl. 4), IV6-IV12 (2004).
22. Bö, L., Geurts, J. J., Ravid, R. & Barkhof, F. Magnetic resonance imaging as a tool to examine the neuropathology of multiple sclerosis. Neuropath. Appl. Neurobiol. 30, 106-117 (2004).
23. Schmierer, K., Scaravilli, F, Altmann, D. R., Barker, G. J. & Miller, D. H. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann. Neurol, 56, 407-415 (2004).
24. Schmierer, K. et al. Quantitative magnetization transfer imaging in postmortem multiple sclerosis brain. J. Magn. Reson. Imaging 26, 41-51 (2007).
25. Giacomini, P. S. & Arnold, D. L. Non-conventional MRI techniques for measuring neuroprotection, repair and plasticity multiple sclerosis. Curr. Opin. Neurol. 21, 272-277 (2008).
26. van den Elskamp, I. J. et al. Persistent T1 hypointensity as an MRI marker for treatment efficacy in multiple sclerosis. Mult. Scler. 14, 464-469 (2008).
27. MacKay, A. L. et al. MR relaxation in multiple sclerosis. Neuroimaging Clin. N. Am. 19, 1-26 (2009).
28. Bjartmar, C. & Trapp, B. D. Axonal degeneration and progressive neurological disability in multiple sclerosis. Neurotox. Res. 5 157-164 (2003).
29. Ceccamlli, A. et al. Normal-appearing white and grey matter damage in MS. A volumetric and diffusion tensor MRI study at 3.0 Tesla. J. Neurol. 254, 513-518 (2007).
30. Davies, G. R. et al. Normal-appearing grey and white matter T1 abnormality in early relapsing-remitting multiple sclerosis: A longitudinal study. Mult. Scler. 13, 169-177 (2007).
31. Roosendaal, S. D. et al. Regional DTI differences in multiple sclerosis patients. Neuroimage 44, 1397-1403 (2009).
32. Reich, D. S. et al. Damage to the optic radiation in multiple sclerosis is associated with retinal injury and low contrast visual acuity. Arch. Neurol. in press (2009).
33. Miller, D. H., Thompson, A. J. & Filippi, M. Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis. J. Neurol. 250, 1407-1419 (2003).
34. Rovaris, M. et al. Optimizing diffusion measurements for large-scale, multicenter multiple sclerosis trials: A pan-European study. Mult. Scler. 14 (Suppl.), S216 (2008).
35. Narayanan, S. et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J. Neurol. 248, 979-986 (2001).
36. Khan, O. et al. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult. Scler. 11, 646-651 (2005).
37. Kutzelnigg, A. et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128, 2705-2712 (2005).
38. Stevenson, V. L. et al. Spinal cord atrophy and disability in MS: a longitudinal study. Neurology 51, 234-238 (1998).
39. Gilmore, C. et al. Spinal cord grey matter lesions in multiple sclerosis detected by post-mortem high field MR imaging. Mult. Scler. 15, 180-188 (2009).
40. Bot, J. C. et al. Spinal cord abnormalities in recently diagnosed MS patients: Added value of spinal MRI examination. Neurology 62, 226-233 (2004).
41. Jacobi, C, et al. Prospective combined brain and spinal cord MRI in clinically isolated syndromes and possible early multiple sclerosis: impact on dissemination in space and time. Eur. J. Neurol. 15 1359-1364 (2008).
42. Agosta, F. et al. In vivo assessment of cervical cord damage in MS patients: A longitudinal diffusion tensor MRI study. Brain 130 2211-2219 (2007).
43. Ciccarelli, O. et al. Spinal cord spectroscopy and diffusion-based tractography to assess acute disability in multiple sclerosis. Brain 130, 2220-2231 (2007).
44. DeBoy, C. A. et al. High resolution diffusion tensor imaging of axonal damage in focal inflammatory and demyelinating lesions in rat spinal cord. Brain 130, 2199-2210 (2007).
45. Budde, M, D. et al. Toward accurate diagnosis of white matter pathology using diffusion tensor imaging. Magn. Reson. Med. 57 688-695 (2007).
46. Sun, S. W., Liang, H. F., Cross, A. H. & Song, S. K. Evolving Walledan degeneration after transient retinal ischemia in mice characterized by diffusion tensor imaging. Neuroimage 40, 1-10 (2008).
47. Sun, S. W., Liang, H. F., Xie, M., Oyoyo, U. & Lee, A. Fixation, not death, reduces sensitivity of DTI in detecting optic nerve damage. Neuroimage 44, 611-619 (2009).
48. Kalkers, N. F., Barkhof, F., Bergers, E., van Schijndel, R. & Polman, C. H. The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: A pilot study. Mult. Scler. 8, 532-533 (2002).
49. Balcer, L. J. et al. New low-contrast vision charts: Reliability and test characteristics in patients with multiple sclerosis. Mult. Scler. 6, 163-171 (2000).
50. Baier, M. L. et al. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis. Neurology 64, 992-995 (2005).
51. Wu, G. F. et al. Relation of vision to global and regional brain MRI in multiple sclerosis. Neurology 69, 2128-2135 (2007).
52. Balcer, L. J. et al. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology 68, 1299-1304 (2007).
53. Trip, S. A. et al. Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann. Neurol. 58, 383-391 (2005).
54. Fisher, J. B. et al. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology 113 324-332 (2006).
55. Pulicken, M. et al. Optical coherence tomography and disease subtype in multiple sclerosis. Neurology 69, 2085-2092 (2007).
56. Gordon-Lipkin, E. et al. Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology 69, 1603-1609 (2007).
57. Cettomai, D. et al. Reproducibility of optical coherence tomography in multiple sclerosis. Arch. Neurol. 65, 1218-1222 (2008).
58. Costello, F. et al. Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann. Neurol. 59, 963-969 (2006).
59. Ciccarelli, O. et al. Optic radiation changes after optic neuritis detected by tractography-based group mapping. Hum. Brain Mapp. 25, 308-316 (2005).
60. Audoin, B. et al. Selective magnetization transfer ratio decrease in the visual cortex following optic neuritis. Brain 129, 1031-1039 (2006).
61. Hickman, S. J. et al. Optic nerve diffusion measurement from diffusion-weighted imaging in optic neuritis. Am. J. Neuroradiol. 26, 951-956 (2005).
62. Trip, S. A. et al. Optic nerve atrophy and retinal nerve fibre layer thinning following optic neuritis: Evidence that axonal loss is a substrate of MRI-detected atrophy. Neuroimage 31, 286-293 (2006).
63. Trip, S. A. et al. Optic nerve magnetization transfer imaging and measures of axonal loss and demyelination in optic neuritis. Mult. Scler. 13, 875-879 (2007).
64. Wegner, C. et al. Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multicentre fMRI study. Eur. J. Neurol. 15, 113-122 (2008).
65. Bosnell, R. et al. Reproducibility of fMRI in the clinical setting: Implications for trial designs. Neuroimage 42, 603-610 (2008).
66. Filippi, M. & Rocca, M. A. Application of fMRI to the study of multiple sclerosis: An update. Future Neurol. 3, 141-151 (2008).
67. Parry, A. M., Scott, R. B., Palace, J., Smith, S. & Matthews, P. M. Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine. Brain 126, 2750-2760 (2003).
68. Rocca, M. A. et al. fMRI changes in relapsing-remitting multiple sclerosis patients complaining of fatigue after IFN beta-1a injection. Hum. Brain Mapp. 28, 373-382 (2007).
69. Xiang, Z. et al. Detection of myelination using a novel histological probe. J. Histochem. Cytochem. 53, 1511-1516 (2005).
70. Stankoff, B. et al. Imaging of CNS myelin by positron-emission tomography. Proc. Natl Acad. Sci. USA 103, 9304-9309 (2006).
71. Wu, C, et al. A novel fluorescent probe that is brain permeable and selectively binds to myelin. J. Histochem. Cytochem. 54, 997-1004 (2006).
72. Vowinckel, E. et al. PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis. J. Neurosci. Res. 50, 345-353 (1997).
73. Banati, R. B. et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: Quantitative in vivo imaging of microglia as a measure of disease activity. Brain 123, 2321--2337 (2000).
74. Debruyne, J.C. et al. PET visualization of microglia in multiple sclerosis patients using [11C] PK11195. Eur. J. Neurol. 10, 257-264 (2003).
75. Rashid, W. et al. Abnormalities of cerebral perfusion in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 75, 1288-1293 (2004).
76. Adhya, S. et al. Pattern of hemodynamic impairment in multiple sclerosis: Dynamic susceptibility contrast perfusion MR imaging at 3.0 T. Neuroimage 33, 1029-1035 (2006).
77. Wuerfel, J., Paul, F. & Zipp, F. Cerebral blood perfusion changes in multiple sclerosis. J. Neurol. Sci. 259, 16-20 (2007).
78. Inglese, M. et al. Perfusion magnetic resonance imaging correlates of neuropsychological impairment in multiple sclerosis. J. Cereb. Blood Flow Metab. 28, 164-171 (2008).
79. Ben-Hur, T. et al. Serial in vivo MR tracking of magnetically labeled neural spheres transplanted in chronic EAE mice. Magn. Reson. Med. 57, 164-171 (2007).
80. Zhu J., Zhou, L. & Xing Wu, F. Tracking neural stem cells in patients with brain trauma. N. Engl. J. Med. 355, 2376-2378 (2006).
81. Walczak, P. & Bulte, J. W. M. The role of noninvasive cellular imaging in developing cell-based therapies for neurodegenerative disorders. Neurodegenerative Dis. 4, 306-313 (2007).
82. Gilad, A. A. et al. Artificial reporter gene providing MRI contrast based on proton exchange. Nat. Biotechnol. 25, 217-219 (2007).
83. Vavasour, I. M. et al. Longitudinal changes in myelin water fraction in two MS patients with active disease. J. Neurol. Sci. 276, 49-53 (2009).